Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jang, You-Jin | - |
dc.contributor.author | Kim, Jong-Han | - |
dc.contributor.author | Park, Sung-Soo | - |
dc.contributor.author | Park, Seong-Heum | - |
dc.contributor.author | Kim, Seung-Joo | - |
dc.contributor.author | Kim, Chong-Suk | - |
dc.contributor.author | Mok, Young-Jae | - |
dc.date.accessioned | 2021-09-07T05:35:58Z | - |
dc.date.available | 2021-09-07T05:35:58Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2011-12 | - |
dc.identifier.issn | 0022-4804 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/111020 | - |
dc.description.abstract | Background. The objective of this study was to compare the chemosensitivity of primary tumor and metastasized lymph node from patient with gastric adenocarcinoma. Materials and Methods. We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008. The chemosensitivity of primary tumor and metastatic lymph node were studied using an adenosine triphosphate-based chemotherapy response assay (ATP-CRA). Results. The concordance rate of the ATP-CRA test was 30.8% (8/26). The concordance rate between primary tumor and metastatic N2 group lymph node was only 9.1% (1/11). The metastatic tumor inhibition rates with 5-fluorouracil, cisplatin, doxorubicin, and oxaliplatin were higher than the inhibition rates for primary tumor. Tumor inhibition rates was significantly different between primary tumor and metastatic tumor after doxorubicin treatment (27.734 +/- 20.95 versus 38.403 +/- 26.87, P = 0.021). We detected simple correlations of tumor inhibition rates between primary and metastatic tumors with cisplatin (r = 0.661, P < 0.001) and doxorubicin (r = 0.475, P = 0.031). Conclusions. We observed differences between first choice chemotherapeutic agents based on ATPCRA tests of primary tumor and metastatic tumor in lymph node. Therefore, chemotherapeutic agents should be carefully selected for adjuvant chemotherapy using a chemosensitivity test. (C) 2011 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.subject | CHEMOTHERAPY RESPONSE ASSAY | - |
dc.subject | ADJUVANT CHEMOTHERAPY | - |
dc.subject | COLORECTAL-CANCER | - |
dc.subject | PHASE-III | - |
dc.subject | SURGERY | - |
dc.subject | TUMOR | - |
dc.subject | 5-FLUOROURACIL | - |
dc.subject | HISTOCULTURE | - |
dc.subject | THERAPY | - |
dc.title | Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jang, You-Jin | - |
dc.contributor.affiliatedAuthor | Kim, Jong-Han | - |
dc.contributor.affiliatedAuthor | Park, Sung-Soo | - |
dc.contributor.affiliatedAuthor | Park, Seong-Heum | - |
dc.contributor.affiliatedAuthor | Kim, Seung-Joo | - |
dc.contributor.affiliatedAuthor | Kim, Chong-Suk | - |
dc.contributor.affiliatedAuthor | Mok, Young-Jae | - |
dc.identifier.doi | 10.1016/j.jss.2010.07.003 | - |
dc.identifier.scopusid | 2-s2.0-81155127531 | - |
dc.identifier.wosid | 000296957900057 | - |
dc.identifier.bibliographicCitation | JOURNAL OF SURGICAL RESEARCH, v.171, no.2, pp.657 - 662 | - |
dc.relation.isPartOf | JOURNAL OF SURGICAL RESEARCH | - |
dc.citation.title | JOURNAL OF SURGICAL RESEARCH | - |
dc.citation.volume | 171 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 657 | - |
dc.citation.endPage | 662 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Surgery | - |
dc.relation.journalWebOfScienceCategory | Surgery | - |
dc.subject.keywordPlus | CHEMOTHERAPY RESPONSE ASSAY | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | SURGERY | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | 5-FLUOROURACIL | - |
dc.subject.keywordPlus | HISTOCULTURE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | chemosensitivity test | - |
dc.subject.keywordAuthor | tumor heterogeneity | - |
dc.subject.keywordAuthor | gastric cancer | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.